Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters
Retrieved on:
Thursday, November 3, 2022
Magistrate, Multimedia, Contempt, Defamation, Business relations, FDA, European Union Intellectual Property Office, Judgement, NY, Breach, The Honourable, Damages, CEO, Modified, EUM, Physician, Federal Trademark Dilution Act, Defendant, District court, Health, Tortious interference, Patient, Efficiency, Aquavit
NEW YORK, Nov. 3, 2022 /PRNewswire/ --Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters.
Key Points:
- NEW YORK, Nov. 3, 2022 /PRNewswire/ --Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters.
- The total award to Aquavit will soon be determined by the Magistrate judge the Honorable Robert W. Lehrburger.
- Aquavit is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies.
- Aquavit focuses on personalized medicine to improve patients' health, maximize the efficiency of the medical community, and support the pharmacoeconomics of payers.